Journal article
Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients
Neuropsychopharmacology (New York, N.Y.), v 44(4), pp 826-833
Mar 2019
PMID: 30375498
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Methadone maintenance is an effective treatment for opioid use disorder, yet many methadone-maintained patients (MMPs) continue to struggle with chronic relapse. The current study evaluated whether functional near-infrared spectroscopy (fNIRS) could identify prefrontal cortex (PFC) markers of ongoing opioid use in MMPs, and whether clinical measures of depression and self-report measures of craving would also be associated with opioid use. MMPs (n = 29) underwent a drug cue reactivity paradigm during fNIRS measurements of PFC reactivity. Self-reported opioid craving (measured by a visual analog scale; 0-100) was collected before and after drug cue reactivity, and depressive symptoms were assessed via the 17-item Hamilton Depression Rating Scale (HAM-D). Hierarchical regression and partial correlations were used to evaluate associations between weekly urine drug screens over a 90-day follow-up period and fNIRS, craving, and HAM-D assessments. Neural response to drug cues in the left lateral PFC, controlling for age, sex, and days in treatment was significantly associated with percent opioid-negative urine screens during follow-up (∆F
= 13.19, p = 0.001, ∆R
= 0.30), and correctly classified 86% of MMPs as either using opioids, or abstaining from opioids (χ
(4) = 16.28, p = 0.003). Baseline craving (p < 0.001) and HAM-D assessment (p < 0.01) were also associated with percent opioid-negative urine screens. Combining fNIRS results, baseline craving scores, and HAM-D scores created a robust predictive model (∆F
= 16.75, p < 0.001, ∆R
= 0.59). These data provide preliminary evidence that the fNIRS technology may have value as an objective measure of treatment outcomes within outpatient methadone clinics. Depressive symptoms and drug craving were also correlated with opioid use in MMPs.
Metrics
Details
- Title
- Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients
- Creators
- Andrew S Huhn - Johns Hopkins MedicineMary M Sweeney - Johns Hopkins MedicineRobert K Brooner - Johns Hopkins MedicineMichael S Kidorf - Johns Hopkins MedicineD Andrew Tompkins - Johns Hopkins MedicineHasan Ayaz - Children's Hospital of PhiladelphiaKelly E Dunn - Johns Hopkins Medicine
- Publication Details
- Neuropsychopharmacology (New York, N.Y.), v 44(4), pp 826-833
- Publisher
- Springer Nature
- Grant note
- R01 DA035246 / NIDA NIH HHS R01 DA040644 / NIDA NIH HHS R21DA035327 / U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) T32DA07209 / U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) R21 DA035327 / NIDA NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems
- Web of Science ID
- WOS:000458386200020
- Scopus ID
- 2-s2.0-85056751414
- Other Identifier
- 991019169563704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Neurosciences
- Pharmacology & Pharmacy
- Psychiatry